Fortress Biotech (FBIO) now holds $256 million in cash and only $39 million in debt following a significant gain from selling its Menkes disease drug. This financial boost gives FBIO a strong balance sheet, enabling it to comfortably pay $16 million in deferred preferred dividends by June 2026. The company appears undervalued, with cash exceeding the combined value of its market cap, debt, preferred stock, and deferred dividends by $24 million. This positions FBIO as a potentially attractive investment opportunity for those interested in undervalued biotech stocks with solid cash reserves.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
NTG Clarity Networks announced new purchase orders and contract renewals totaling about CAD 16.6 million, reflecting strong demand for its software development and digital transformation services. This includes $2.3 million from a real estate client ...
